ClinicalTrials.gg
CompletedNCT00002126Updated Jun 24, 2005

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

A Phase 2 interventional study of Filgrastim in HIV Infections and Cytopenias, sponsored by Amgen. Completed at 22 sites in 2 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
477th of 2,150
250 · median 60
Phase 2
478 of 2,802
7 open now
Registered
4th of 2,802
by date

Among the 2,802 studies in HIV Infections with a site in United States, this one is the 477th largest by enrollment of the 2,150 interventional ones that give a count, is one of 478 in phase 2, and was the 4th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,802 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

To determine, in HIV-infected patients, the efficacy of filgrastim ( recombinant-methionyl human granulocyte-colony stimulating factor; G-CSF ) in preventing grade 4 neutropenia, i.e., absolute neutrophil count (ANC) \< 500 cells/mm3.

Read the detailed description

Patients are randomized to receive subcutaneous G-CSF at one of two different doses or no G-CSF (observation) for 24 weeks. Patients who experience ANC \< 500 cells/mm3 on two consecutive occasions at least 24 hours apart prior to completing the 24-week study period will be considered to have reached the primary study endpoint; those in the observation group who reach the primary endpoint prior to week 24 may begin receiving G-CSF for the remainder of the study period. After 24 weeks, patients may continue G-CSF on a compassionate basis at the investigator's discretion.

03

Conditions studied

  • HIV Infections
  • Cytopenias

Keywords

  • Neutropenia
  • Granulocyte Colony-Stimulating Factor
  • Acquired Immunodeficiency Syndrome
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Antiretroviral agents (e.g., AZT, ganciclovir, ddI, ddC), trimethoprim-sulfamethoxazole (Bactrim), interferon, and amphotericin B ONLY IF patient is on the same dose for at least 14 days prior to study entry (patients may not start or stop these agents within 14 days prior to study entry).

Patients must have:

  • Documented infection OR history of AIDS.
  • \< 200 cells/mm3.
  • (segmental neutrophils plus bands) >= 750 and \< 1000 cells/mm3 within 7 days prior to study entry.
  • of at least 6 months.

NOTE:

  • Stable Kaposi's sarcoma is permitted provided patient does not require myelosuppressive therapy (other than interferon) within 4 weeks prior to study entry.

Prior Medication:

Allowed:

  • Prior antiretroviral agents (e.g., AZT, ganciclovir, ddI, ddC), trimethoprim-sulfamethoxazole (Bactrim), interferon, and amphotericin B.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • other than Kaposi's sarcoma and localized basal or squamous cell carcinoma.
  • Psychiatric, addictive, or other disorder that compromises ability to give .
  • Known to E. coli-derived products.

Prior Medication:

Excluded:

  • G-CSF, other hematopoietic growth factors (except for erythropoietin), or agents within 14 days prior to study entry.

Substance abuse that would compromise compliance.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Enrollment
250 participants

Interventions

06

Study locations

22 sites
  • Univ of Alabama at Birmingham / AIDS Outpatient Clinic
    Birmingham, Alabama 35294, United States
  • Maricopa County Med Ctr
    Phoenix, Arizona 85008, United States
  • CARE Ctr / UCLA Med Ctr
    Los Angeles, California 90095, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Univ Hosp / Univ of Colorado Health Sci Ctr
    Denver, Colorado 80262, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • TheraFirst Med Ctrs Inc
    Fort Lauderdale, Florida 33308, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Univ of Kansas School of Medicine
    Wichita, Kansas 672143124, United States
  • Tulane Univ Med School
    New Orleans, Louisiana 701122699, United States
  • New England Deaconess Hosp
    Boston, Massachusetts 02215, United States
  • SUNY / Health Sciences Ctr at Stony Brook
    Stony Brook, New York 11794, United States
  • Nalle Clinic
    Charlotte, North Carolina 28207, United States
  • Univ Hosp of Cleveland / Case Western Reserve Univ
    Cleveland, Ohio 44106, United States
  • Kaiser Permanente Med Ctr
    Portland, Oregon 97227, United States
  • Univ TX San Antonio Health Science Ctr
    San Antonio, Texas 78284, United States
  • Saint Paul's Hosp
    Vancouver, British Columbia, Canada
  • Sunnybrook Health Science Ctr
    Toronto, Ontario, Canada
  • Toronto Gen Hosp
    Toronto, Ontario, Canada
  • Wellesley Hosp
    Toronto, Ontario, Canada
  • Hotel - Dieu de Montreal
    Montreal, Quebec, Canada
  • Saint Michael's Hosp
    Toronto, Canada
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002126
Lead sponsor
Amgen
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion